← Back to Clinical Trials
Recruiting NCT04688190

NCT04688190 CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04688190
Status Recruiting
Phase
Sponsor Universitätsklinikum Hamburg-Eppendorf
Condition Mitral Regurgitation
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2020-11-01
Primary Completion 2030-12-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2020-11-01 with a primary completion date of 2030-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This multinational, investigator-initiated registry aims to investigate clinical outcomes of patients undergoing transcatheter mitral valve replacement (TMVR). The registry primarily focuses on patients treated with TMVR in real-world clinical practice. Patients evaluated for TMVR but not undergoing the procedure are no longer systematically included. Historical data may include such patients who subsequently underwent alternative treatments, including transcatheter edge-to-edge repair, mitral valve surgery, or medical/conservative therapy.

Eligibility Criteria

Inclusion Criteria: * clinically significant mitral insufficiency * patient underwent screening for TMVI * echocardiography data at baseline (and after TMVI, E2E and surgery) * follow-up of at least 30 days Exclusion Criteria: \- age under 18 years

Contact & Investigator

Central Contact

Sebastian Ludwig, MD

✉ se.ludwig@uke.de

📞 +494074100

Principal Investigator

Lenard Conradi, MD

PRINCIPAL INVESTIGATOR

University of Cologne

Frequently Asked Questions

Who can join the NCT04688190 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Mitral Regurgitation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04688190 currently recruiting?

Yes, NCT04688190 is actively recruiting participants. Contact the research team at se.ludwig@uke.de for enrollment information.

Where is the NCT04688190 trial being conducted?

This trial is being conducted at Tucson, United States, Los Angeles, United States, Tampa, United States, Boston, United States and 11 additional locations.

Who is sponsoring the NCT04688190 clinical trial?

NCT04688190 is sponsored by Universitätsklinikum Hamburg-Eppendorf. The principal investigator is Lenard Conradi, MD at University of Cologne. The trial plans to enroll 1,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology